1.Artificial intelligence in drug development for delirium and Alzheimer's disease.
Ruixue AI ; Xianglu XIAO ; Shenglong DENG ; Nan YANG ; Xiaodan XING ; Leiv Otto WATNE ; Geir SELBÆK ; Yehani WEDATILAKE ; Chenglong XIE ; David C RUBINSZTEIN ; Jennifer E PALMER ; Bjørn Erik NEERLAND ; Hongming CHEN ; Zhangming NIU ; Guang YANG ; Evandro Fei FANG
Acta Pharmaceutica Sinica B 2025;15(9):4386-4410
Delirium is a common cause and complication of hospitalization in the elderly and is associated with higher risk of future dementia and progression of existing dementia, of which 70% is Alzheimer's disease (AD). AD and delirium, which are known to be aggravated by one another, represent significant societal challenges, especially in light of the absence of effective treatments. The intricate biological mechanisms have led to numerous clinical trial setbacks and likely contribute to the limited efficacy of existing therapeutics. Artificial intelligence (AI) presents a promising avenue for overcoming these hurdles by deploying algorithms to uncover hidden patterns across diverse data types. This review explores the pivotal role of AI in revolutionizing drug discovery for AD and delirium from target identification to the development of small molecule and protein-based therapies. Recent advances in deep learning, particularly in accurate protein structure prediction, are facilitating novel approaches to drug design and expediting the discovery pipeline for biological and small molecule therapeutics. This review concludes with an appraisal of current achievements and limitations, and touches on prospects for the use of AI in advancing drug discovery in AD and delirium, emphasizing its transformative potential in addressing these two and possibly other neurodegenerative conditions.
2.Chronic Kidney Disease and Associated Cardiovascular Risk Factors in Chinese with Type 2 Diabetes.
Qing Lin LOU ; Xiao Jun OUYANG ; Liu Bao GU ; Yong Zhen MO ; Ronald MA ; Jennifer NAN ; Alice KONG ; Wing Yee SO ; Gary KO ; Juliana CHAN ; Chun Chung CHOW ; Rong Wen BIAN
Diabetes & Metabolism Journal 2012;36(6):433-442
BACKGROUND: To determine the frequency of chronic kidney disease (CKD) and its associated risk factors in Chinese type 2 diabetic patients, we conducted a cross-sectional study in Nanjing, China, in the period between January 2008 and December 2009. METHODS: Patients with type 2 diabetes under the care by Jiangsu Province Official Hospital, Nanjing, China were invited for assessment. CKD was defined as the presence of albuminuria or estimated glomerular filtration rate <60 mL/min/1.73 m2. Albuminuria was defined as urinary albumin-to-creatinine ratio > or =30 mg/g. RESULTS: We recruited 1,521 urban Chinese patients with type 2 diabetes (mean age, 63.9+/-12.0 years). The frequency of CKD and albuminuria was 31.0% and 28.9%, respectively. After adjusted by age and sex, hypertension, anemia and duration of diabetes were significantly associated with CKD with odds ratio (95% confidence interval) being 1.93 (1.28 to 2.93), 1.70 (1.09 to 2.64), and 1.03 (1.00 to 1.06), respectively. CONCLUSION: In conclusion, CKD was common in the urban Nanjing Chinese with type 2 diabetes. Strategies to prevent or delay progression of kidney disease in diabetes should be carried out at the early disease course of type 2 diabetes.
Albuminuria
;
Anemia
;
Asian Continental Ancestry Group
;
China
;
Cross-Sectional Studies
;
Diabetes Mellitus, Type 2
;
Glomerular Filtration Rate
;
Humans
;
Hypertension
;
Kidney Diseases
;
Odds Ratio
;
Renal Insufficiency, Chronic
;
Risk Factors
3.Validity of Glycated Hemoglobin in Screening and Diagnosing Type 2 Diabetes Mellitus in Chinese Subjects.
Yun YU ; Xiao Jun OUYANG ; Qing Lin LOU ; Liu Bao GU ; Yong Zhen MO ; Gary T KO ; Chun Chung CHOW ; Wing Yee SO ; Ronald MA ; Alice KONG ; Nicola BROWN ; Jennifer NAN ; Juliana CHAN ; Rong Wen BIAN
The Korean Journal of Internal Medicine 2012;27(1):41-46
BACKGROUND/AIMS: The application of glycated hemoglobin (HbA1c) for the diagnosis of diabetes is currently under extensive discussion. In this study, we explored the validity of using HbA1c as a screening and diagnostic test in Chinese subjects recruited in Nanjing, China. METHODS: In total, 497 subjects (361 men and 136 women) with fasting plasma glucose (PG) > or = 5.6 mmol/L were recruited to undergo the oral glucose tolerance test (OGTT) and HbA1c test. Plasma lipid, uric acid, and blood pressure were also measured. RESULTS: Using a receiver operating characteristic curve, the optimal cutoff point of HbA1c related to diabetes diagnosed by the OGTT was 6.3%, with a sensitivity and specificity of 79.6% and 82.2%, respectively, and the area under the curve was 0.87 (95% confidence interval, 0.83 to 0.92). A HbA1c level of 6.5% had a sensitivity and specificity of 62.7% and 93.5%, respectively. When comparing the HbA1c > or = 6.5% or OGTT methods for diagnosing diabetes, the former group had significantly higher HbA1c levels and lower levels of fasting and 2-hour PG than the latter group. No significant difference was observed in the other metabolism indexes between the two groups. CONCLUSIONS: Our results suggest that HbA1c > or = 6.5% has reasonably good specificity for diagnosing diabetes in Chinese subjects, which is in concordance with the American Diabetes Association recommendations.
Aged
;
Analysis of Variance
;
*Asian Continental Ancestry Group
;
Biological Markers/blood
;
Blood Glucose/analysis
;
China/epidemiology
;
*Chromatography, High Pressure Liquid/standards
;
*Chromatography, Ion Exchange/standards
;
Diabetes Mellitus, Type 2/blood/*diagnosis/ethnology
;
Fasting/blood
;
Female
;
Glucose Tolerance Test/standards
;
Hemoglobin A, Glycosylated/*analysis
;
Humans
;
Male
;
Mass Screening/*methods/standards
;
Middle Aged
;
Predictive Value of Tests
;
ROC Curve
;
Reference Standards
;
Reproducibility of Results
;
Sensitivity and Specificity

Result Analysis
Print
Save
E-mail